CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 493 enrolled
Drug / intervention
Alogliptin and pioglitazone +2 moredrug
Likely dose
Alogliptin and pioglitazone 12.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00286494
NCT00286494Phase 3Completed
CompareCT.gov

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Pioglitazone in Subjects With Type 2 Diabetes Mellitus

Takeda·interventional·Posted Feb 3, 2006·Updated Feb 3, 2012

In Brief

A Phase 3 clinical trial evaluating Alogliptin and pioglitazone and Pioglitazone for Diabetes Mellitus. Completed, enrolled 493 participants across 77 sites in 14 countries.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with pioglitazone in adults with type 2 diabetes mellitus

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus
CountriesArgentina, Australia, Brazil, Czechia, Germany, Guatemala, Hungary, India, Mexico, Netherlands, New Zealand, Peru, South Africa, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 3, 2006
Enrollment StartFeb 1, 2006
Primary CompletionAug 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 20.4 years ago

Interventions

Alogliptin and pioglitazonedrug

Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks

Alogliptin and pioglitazonedrug

Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks

Pioglitazonedrug

Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks